Study clarifies best treatments for uncommon kidney cancers
the ONA take:
Researchers at Duke Cancer Institute led a study comparing two biologic therapies used to treat a subset of advanced kidney cancers.
The head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of these cancers.
The study focused on three form of non-clear cell kidney cancers: metastatic papillary, chromophobe, or unclassified. In the study, 108 patients were randomly assigned to receive either everolimus or sunitinib, the two treatments approved for these cancers, until their tumors progressed.
The findings show that sunitinib was superior overall at prolonging the time to tumor regrowth, but at a higher rate of severe toxicity.
Sunitinib was also more effective for papillary-type kidney cancers and for better prognosis patients. Everolimus offered longer median progression-free survival for patients with chromophobe and poor-risk tumors.
In addition, more than 100 study participants donated tumor tissue. The researchers now have the largest repository of non-clear cell kidney cancer tissue to aid in further research toward developing new drugs and identifying biomarkers for the disease.
Head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of kidney cancers.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|